A B S T R A C T Previous studies of the ability of the immature heart to respond to glucagon have yielded conflicting results. To test the possibility that the apparent discrepancies might be explained in part by species variability, isolated hearts of fetal mice and rats (13-22 days' gestational age) were studied under identical conditions in vitro. Changes in atrial rate and ventricular contractility were measured in spontaneously beating hearts exposed to glucagon, and activation of adenylate cyclase was assayed in cardiac homogenates.
INTRODUCTION
As the immature heart develops, it gradually acquires the ability to respond to cardioactive agents. The point during development at which pharmacological responsiveness appears may vary widely for different agents. For example, cardiac responsiveness to the physiological neurotransmitters, acetylcholine and norepinephrine, ac-tually precedes innervation of the heart (1, 2), whereas such agents as tyramine have no effect until later (2) . Analysis of the patterns of maturation of contractile and metabolic responsiveness to various drugs has been suggested as a useful means for gaining insight into possible mechanisms of action of the drugs (2) .
Responsiveness to glucagon has been reported to appear especially late in cardiac development. Indeed, some experiments have indicated that the heart remains completely insensitive to the drug until long after birth (3) (4) (5) . On the other hand, glucagon has been said to cause an increase in the spontaneous beating rate of hearts of fetal mice well before term (2) . The experiments that yielded these apparently conflicting results were performed in different species as well as under different protocols; accordingly, to resolve the discrepancies, the present protocol was designed to evaluate in detail the comparative maturation of chronotropic, inotropic, and metabolic responses to glucagon in hearts of fetal mice and of fetal rats of various gestational ages. In addition, experiments were made to test the ability of glucagon to activate myocardial adenylate cyclase at various stages of fetal development in the two species in order to correlate the presence of enzyme activation with the ability of the hearts to alter their beating. Finally, the effect of glucagon on cyclic AMP concentration in fetal mouse hearts was studied as well.
METHODS
Experiments were conducted in three separate phases. Measurements of cardiac contraction and glycogen content were made in Dallas by techniques described by Wildenthal et al. (2, 6) and Karlsson (7) . Adenylate cyclase activity in fresh cardiac homogenates was measured in Indianapolis by techniques described below. Measurements of cyclic AMP were made after treating spontaneously beating hearts with glucagon or norepinephrine and freezing them in liquid nitrogen in Dallas, and assaying the tissue for cyclic AMP in Indianapolis.
Studies of cardiac beating and glycogen content. Intact hearts were removed from mouse and rat fetuses of known gestational ages ranging between 13 and 22 days (term is 20-22 days in both species). The hearts were dissected free of surrounding tissue and transferred to specially constructed chambers where they lay on stainless steel grids with their lower surfaces exposed to liquid medium 199 (Grand Island Biological Co., Grand Island, N. Y.) and their top surfaces protruding into the atmosphere (6) .
For studies of beating rate, the entire heart with both atria intact was used; for measurements of inotropism and of glycogen content, the atria were removed and the isolated ventricles alone were transferred to the chamber. In either instance, the myocardium beat spontaneously and rhythmically, with a stable rate and strength of contraction throughout the experiment (2, 6). After initial stabilization in an incubator for 2 h at 37'C, 95% 02, and pH 7.4, the chamber with its heart was transferred to a water bath in room air. The medium was replaced with fresh control medium, and the rate and strength of contraction were recorded. Then the medium was changed to an identical solution supplemented with 10 /AM glucagon (Eli Lilly and Company, Indianapolis, Ind., or Sigma Chemical Co., St. Louis, Mo.) and repeat recordings were made after a 45-60-s period of stabilization. This concentration of glucagon was determined in preliminary studies to provide a maximal response: lower concentrations gave submaximal responses, higher levels failed to augment further the rate or strength of contraction at any age, and concentrations of 0.1 mM or more occasionally even induced toxic effects (i.e., arrhythmias or depressed contractility). In some experiments a maximally effective concentration of norepinephrine (10 /LM) was tested in a similar manner for comparison to the glucagon response, and both agents were also tested in the presence of 0.1 mM propranolol.
Recordings of contractions were obtained with a specially constructed microcapacitance-probe that has been described previously (6) . The device detects movements in space of the isotonically beating hearts; changes in the speed and extent of displacement of the hearts can be recorded as a function of changes in inotropic state while beating rate is monitored simultaneously.
For analyses of cardiac glycogen content after glucagon treatment, hearts were allowed to stabilize for 2 h as described above. Then, the medium for the experimental heart was replaced with solution containing 10 /AM glucagon, while the medium for a control heart (taken from a matched littermate of the experimental animal and prepared identically was simultaneously replaced with fresh control medium. The hearts were then reincubated at 370C, 95%
Os, and pH 7.4 for 30 min, after which they were frozen in liquid nitrogen and subsequently assayed for glycogen as described by Karlsson (7) .
Studies of adenylate cyclase actizity in cardiac homogenates. Analyses of adenylate cyclase activity were performed as previously described (5, 8 Comparison studies were made with liver homogenates from 18-day fetal mice. Conditions were similar to those described above for heart and those described previously for fetal rat liver (5) .
Studies of tissue levels of cyclic AMP. Intact hearts from 20-21 day fetal mice were prepared as if for studies of beating (see above). To provide sufficient tissue for the assays, six hearts were placed on each grid and subsequently pooled as one sample. After stabilization for 2-3 h in 95% oxygen, the hearts were exposed to fresh control medium, 10 AM glucagon, or 10 AM norepinephrine. Beating rates were monitored over the next 20-180 s, after which the hearts were rapidly frozen in liquid nitrogen. It required less than 0.5 s to transfer each individual beating heart from the grid to the liquid nitrogen, but since multiple hearts were transferred for each sample, the difference in the duration of exposure to the drug from the first to the last heart of each sample spanned approximately 10 FIGuRE 2 Atrial rate response to glucagon and norepinephrine in 21-day fetal mouse hearts. Hearts of matched littermates were tested with glucagon in the presence (n = 6) or absence (n = 4) of propranolol or with norepinephrine in the presence (n =4) or absence (n =4) of propranolol. Propranolol had no significant effect on the atrial response to glucagon (P > 020), but significantly inhibited the response to norepinephrine (P <0.01). Symbols as in Fig. 1 .
*-*, no propranolol; ----0, 100 AM propanolol.
1 N HCl, [H8]cyclic AMP (0.5 pmol; 0.1 ,uCi) was added, and the samples were centrifuged at 2,500 g for 10 min. The supernate was extracted five times with 2.5 vol of watersaturated diethyl ether. The samples were further purified by ion exchange chromatography (10) and assayed for cyclic AMP by the method of Gilman (11) hearts, whereas hearts from fetuses of more than 19 days' gestational age always responded. [17] [18] days, responses were small and inconsistent. As is apparent in Fig. 3 , changes in the older hearts were characterized by increases in the total extent of displacement and in the maximal rate of displacement of the ventricles; simultaneously, there was little or no change in the time to peak displacement or in the total duration of contraction. These changes in the presence of glucagon are indicative of an improvement in inotropic state and are similar to those normally encountered in myocardium tested with conventional techniques. Most of the isolated ventricles from late-fetal mice increased their rate of beating as well as their strength of contraction after exposure to glucagon. However, in a few, such as the one illustrated in Fig. 3 , there was only a minimal change in heart rate; nevertheless, there still occurred an increase in contractility. Thus, the inotropic alteration could not be explained merely as a passive consequence of tachycardia; rather, it apparently represented a primary change in the contractile state of the heart induced by glucagon. Usually the increased contractility began gradually after a latent period of In the younger mouse hearts glucagon failed to activate adenylate cyclase, just as it failed to alter beating at that age (Table II) . Unlike the situation with chronotropic and inotropic responsiveness, however, further fetal maturation was not accompanied by the appearance of adenylate cyclase activation in response to the drug. Rather, even in the oldest fetal mouse hearts tested, glucagon had no effect on adenylate cyclase ac- (Table II) . Furthermore, there was no evidence that fetal mouse tissues in general were unresponsive to glucagon: liver homogenates from 18-day fetuses displayed concentration-dependent increases of adenylate cyclase activity over a range of 2 nM-20 iAM glucagon, with a fourfold rise at maximal concentrations (Table III) .
The apparent disparity between the ability of glucagon to stimulate beating in late-fetal mouse hearts and its inability to stimulate cardiac adenylate cyclase in vitro might imply that the action of the enzyme is not important in mediating the hormone's chronotropic and inotropic effects. On the other hand, it might simply mean that the glucagon receptor is labile in this tissue and susceptible to damage or solubilization during the trauma of homogenization. To distinguish between these possibilities it seemed necessary to demonstrate the presence or absence of increased cyclic AMP formation in beating hearts that developed tachycardia and increased contractility in response to glucagon. Accordingly, hearts were frozen 30 s-3 min after exposure to glucagon and subsequently assayed for cyclic AMP. Results for all samples are shown in Table IV . Concentrations of cyclic AMP were not significantly increased after exposure to glucagon, despite the fact that beating rate and contractile strength were observed to increase in the same hearts. This was not a general unresponsiveness, since in other experiments norepinephrine caused consistent increases in tissue cyclic AMP under identical circumstances (Table IV) .
As shown in Fig. 4 , concentrations of cyclic AMP were unchanged after exposure to glucagon for 30 s (i.e., just as increased contractility and heart rate were becoming apparent), 1 min (when maximal ventricular responses were appearing), 2 min (by which time all hearts were responding maximally), or 3 min. In contrast, increases in cyclic AMP after norepinephrine averaged 33±6 pmol/mg after 30 s-i min (six hearts), 23±8 pmol/mg after 2 min (five hearts), and 18±7 pmol/mg after 3 min (three hearts).
Rats. Hearts of rat fetuses aged 16 days responded to glucagon exactly as did mouse hearts of the same age; that is, they displayed no changes in beating or glycogen content. Responses of late-fetal hearts were distinctly different in the two species, however: unlike mouse hearts, hearts from fetal rats remained completely insensitive to the drug even late in gestation.
Atrial rate was not altered significantly by 10 sM glucagon at 16 days gestation (mean change, -3±2 beats/min), at 17-18 days (mean change, + 1±3 beats/ min), or at term (mean change, -1±3 beats/min). Similarly, neither the amplitude nor the duration of contraction, as measured from recordings of ventricular motion with the capacitance probe, was affected by glucagon at any fetal age. Glycogen content also remained unchanged (Table I) .
Finally, in agreement with previous experiments from the laboratory of Clark et al. (5), adenylate cyclase activity in homogenates of fetal rat hearts was not significantly increased in the presence of glucagon, even though epinephrine and NaF exerted their usual stimulatory effect. Thus, cyclase activity in cardiac homogenates from 18-day fetal rats was 166+10 pmol/mg protein/15 min under unstimulated basal conditions, as compared to 180±7 after 10 AM glucagon (n = 4 in each group; P > 0.10), while epinephrine (10 eM) increased activity to 337+10 and NaF (10 mM) increased activity to 1,064 (P < 0.001 for both). In 21-22 day fetal hearts, the comparable values were 244±6 (control), 295±29 (glucagon, P > 0.10), 369+8 (epinephrine, P <0.001), and 1,467 (NaF, P <0.001). DISCUSSION The data obtained in this study demonstrate that the appearance of cardiac responsiveness to glucagon occurs at around 17-18 days' gestational age in the mouse fetus, well before term. In contrast, as suggested previously by Clark et al. (5) , functional maturation of cardiac responsiveness to glucagon in the rat appears not to occur until after birth, although some laboratories have reported binding of glucagon and activation of adenylate cyclase in homogenates of fetal rat hearts (12) . Previous studies from other laboratories have suggested that hearts of lambs, like those of rats, fail to respond functionally to glucagon in the fetal and newborn period (3, 4) . Thus, apparent discrepancies in previous reports of glucagon's actions in fetal and newborn hearts may be simply a function of species differences. By extrapolation these findings suggest that evaluations of pharmacological maturation and differentiation of receptor sites should always be controlled for species variability, whatever the drug being tested. It is also essential to document accurately the exact age of the animal being studied. Major changes in responsiveness may occur in just a few days, so that unmodified descriptions of "fetal responsiveness" can be potentially misleading if the exact stage of gestation is not defined precisely.
A corollary of this point is that species and age differences might serve as a great aid in efforts to dissect out the mechanism of action of drugs. Thus, as Friedman and his colleagues (4) have implied, observations that the onset of inotropic and chronotropic responsiveness to glucagon coincide with the appearance of adenylate cyclase activation may lend support to (but certainly do not prove) the hypothesis that the drug's effects on beating are mediated through adenylate cyclase (13) . On the other hand, it has been suggested (2) that if a species could be identified in which maturation of chronotropic and inotropic responsiveness truly precedes the ability of the enzyme to be activated by a drug, that would provide impressive evidence that the enzyme's actions do not cause the observed changes in beating.
The appearance of marked chronotropic and inotropic responsiveness to glucagon by 19-21 days' gestation in the mouse implies that membrane receptor sites and all other essential components of the cellular machinery involved with mediating the drug's actions on beating are fairly mature by that time. Simultaneously, the drug apparently cannot activate adenylate cyclase in homogenates of the cardiac tissue. This disparity might imply that the action of the enzyme is not vital to glucagon's effects on beating, or it might merely reflect an unusual lability of the enzyme in fetal hearts. The inability to demonstrate an increase in cyclic AMP levels of beating hearts lends support to the possibility that the former alternative may be correct. It also should be pointed out, however, that one cannot rule out the possibility that increases in a particular pool of cyclic AMP may have occurred that were too small for detection grossly but which could have been of critical importance for beating. Such a critically important pool could occur theoretically in a small subcellular compartment of all cells or, as suggested by the work of Venter et al. (14) , possibly even in only a few cells from which an impulse for increased strength of contraction might somehow be propogated throughout the tissue without all cells actually being exposed to the hormone. Whatever the ultimate explanation may be for the observed disparity between glucagon's biochemical and contractile effects in fetal mouse hearts, the present results indicate that the interrelation between the drug's ability to augment beating and its ability in many species to activate cyclase and cause gross increases in cyclic AMP may be, at the very least, more complex than is often supposed.
Preliminary data indicate that the apparent inability of homogenates of mouse hearts to display activation of adenylate cyclase after exposure to glucagon extends even into adulthood (15) , suggesting that the disparities observed may not be peculiar to the fetus but may occur at all ages in this species. It is of interest in this regard that Henry and his co-workers (16) have presented convincing evidence that the guinea pig is another species that displays a disparity between glucagon's effects on beating and its effects on adenylate 556 cyclase and cyclic AMP. Thus glucagon causes a maximal increase in contractility at 10 ALM in the adult guinea pig heart, but has no significant effect on adenylate cyclase activity or total cyclic AMP content (16) . In the adult rat heart, on the other hand, maximal inotropic changes also occur at 10 FM, but these changes, which are of a similar magnitude as in guinea pig, are accompanied by significant dose-dependent increases in cyclase activity and cyclic AMP content (5, 16, 17) . Again, in the guinea pig heart as in fetal mouse heart, available data cannot yet rule out the possibility of immeasureably small but critically important increases in cyclic AMP in an isolated pool.
The present data demonstrate a disparity not only between activation of the adenylate cyclase system by glucagon and changes in beating but also between cyclase activation and glycogen depletion. We do not feel, however, that the present data are sufficient to suggest a conclusion that glucagon-induced glycogenolysis is not mediated by cyclic AMP accumulation: the amount of glycogen depletion observed was small and could easily have occurred secondarily, because of increased energy demands by the rapidly beating hearts, rather than as a primary metabolic action of glucagon. Furthermore, we have found that adult mouse hearts fail to respond to glucagon with an increase in phosphorylase activity or glycogenolysis in vivo, despite a positive chronotropic response (Clark et al., unpublished data), suggesting that the glycogenolysis observed in fetal hearts in vitro was not a direct consequence of glucagon's metabolic actions.
Finally, it should be mentioned that the concentration of glucagon required to affect the heart optimally in this study, as in other previous ones, was much higher than occurs physiologically. Thus, the present observations probably have more applicability to cardiac pharmacology and to evaluations of receptor differentiation than to normal physiology. However, the recent incursion of clinical cardiologists into this area has insured that evaluations of pharmacological glucagon responsiveness have more than theoretical relevance: as long as glucagon continues to be proposed and used clinically as an inotropic drug, the need to define the conditions under which it is effective and the mechanisms by which it acts on the heart will remain vital (18) .
